Akari Therapeutics PLC (NASDAQ:AKTX) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Monday.
Several other research firms also recently commented on AKTX. Zacks Investment Research downgraded shares of Akari Therapeutics PLC from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 23rd. Chardan Capital upgraded shares of Akari Therapeutics PLC from a “sell” rating to a “neutral” rating and decreased their price objective for the company from $6.50 to $6.00 in a report on Wednesday, May 31st. Canaccord Genuity reiterated a “buy” rating and issued a $15.00 price objective (down from $33.00) on shares of Akari Therapeutics PLC in a report on Monday, June 26th. Finally, William Blair reiterated an “outperform” rating on shares of Akari Therapeutics PLC in a report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $7.17.
Shares of Akari Therapeutics PLC (AKTX) opened at 5.85 on Monday. Akari Therapeutics PLC has a one year low of $3.18 and a one year high of $22.20. The company’s market capitalization is $68.89 million. The firm has a 50-day moving average of $3.96 and a 200-day moving average of $7.26.
COPYRIGHT VIOLATION WARNING: This story was published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/2887871/valuengine-upgrades-akari-therapeutics-plc-aktx-to-sell.html.
An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Hikari Power Ltd acquired a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned about 0.51% of Akari Therapeutics PLC at the end of the most recent reporting period. Institutional investors and hedge funds own 26.85% of the company’s stock.
Akari Therapeutics PLC Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.